Erlotinib Completed Phase 2 Trials for Recurrent Skin Squamous Cell Carcinoma / Metastatic Skin Squamous Cell Carcinoma / Skin Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01198028Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma